Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 5,902 shares at $30.57 ($181K) on 2023-06-01, disclosed to the SEC on 2023-06-05.
Scheduled sale ($181k) by CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.57 | 2,701 | $83K | 45.7% |
| 2 | $30.57 | 2,701 | $83K | 45.7% |
| 3 | $31.00 | 500 | $16K | 8.6% |
| Total | $30.61 avg | 5,902 | $181K | 100% |
| Filing → |
| RVNC | SELL | 2023-07-05 | $43K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |
| RVNC | SELL | 2023-05-02 | $203K | — | Filing → |